Searchable abstracts of presentations at key conferences in endocrinology

ea0066p8 | Bone | BSPED2019

Clinical, functional and quality of life outcomes of Burosumab therapy in children with X-linked hypophosphoataemia: a real world, London experience

Sandy Jessica , Gilbey-Cross Robyn , Santos Rui , Sakka Sophia , Cocca Alessandra , Morris Mavali , Massey Jill , Cheung Moira

Burosumab, monoclonal antibody targeting fibroblast growth factor 23, is now available for clinical use in children with X-linked hypophosphatemia (XLH). We explored the effects of this treatment in a clinical setting, considering biochemistry, growth, deformity, functionality, quality of life, pain and fatigue.Methods: Clinical, biochemical, radiological and questionnaire data were reviewed at 6 and 12 months(m) for 8 children with XLH starting burosuma...

ea0044cc9 | Featured Clinical Cases | SFEBES2016

Successful treatment of primary aldosteronism with partial adrenalectomy, facilitated by the use of 11C-Metomidate PET/CT

Bashari Waiel , Powlson Andrew , Koulouri Olympia , Quill Denis , Brown Morris , Cheow Heok , Dennedy Michael Conall , Gurnell Mark

Background: Primary aldosteronism (PA) is responsible for 5-10% of all cases of HTN. The current gold standard test for determining the side of aldosterone hypersecretion is adrenal vein sampling (AVS). 11C-Metomidate PET/CT (METO-PET) has recently emerged as a potential non-invasive alternative to AVS. As 11C-Metomidate is concentrated within ‘hyperfunctioning’ nodules, METO-PET potentially not only identifies the side, but the exact site of al...

ea0038p212 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2015

Distinguishing different subtypes of aldosterone-producing adenoma by histological, immunohistochemical and radiological features; a basis for individualised treatment strategies in primary aldosteronism?

Powlson Andrew S , Teo Ada , Haris Lalarukh , Maniero Carmela , Marker Alison , Azizan Elena , Gurnell Mark , Brown Morris J

Background: Primary aldosteronism (PA) is now recognised to account for 5–10% of all cases of hypertension (and 20–25% of refractory hypertension). For patients with a demonstrable unilateral cause, adrenalectomy offers the potential for cure of PA, although resolution of hypertension occurs in only ~50% of patients. We have examined histological appearances and radiological features in patients with APAs undergoing adrenalectomy in an attempt to further our understa...

ea0034p365 | Steroids | SFEBES2014

11C-metomidate PET–CT in primary hyperaldosteronism: a valuable alternative to AVS

Powlson Andrew S , Koulouri Olympia , Challis Benjamin G , Cheow H K , Buscombe John , Koo Brendan , Brown Morris J , Gurnell Mark

Although adrenal vein sampling (AVS) remains the gold-standard for distinguishing unilateral and bilateral disease in primary hyperaldosteronism (PHA), it is technically demanding and not always feasible. Metomidate (MTO), a potent inhibitor of CYP11B1 and CYP11B2, can be C11H3-labelled as a PET tracer (11C-MTO), and we have previously shown it to be an alternative to AVS for localising unilateral aldosterone-producing adenomas (APAs) (Burton <...

ea0019p353 | Thyroid | SFEBES2009

Thyroid dysfunction in a Hepatitis C population treated with interferon therapy

Costelloe S , Wassef N , Morris C , Schulz J , Vaghjani T , Thomas M , Jacobs M , Dusheiko G , Vanderpump M

Interferon alpha (IFNα) and Ribavirin combination therapy effectively eradicates Hepatitis C Virus (HCV) in up to 80% of patients. Transient thyroid dysfunction (TD) (>80% hypothyroidism) usually due to a destructive thyroiditis has been recognised to occur in up to 25% of patients treated in Italy, Japan and Australia. However, data are lacking in a UK cohort and no standardised protocol for testing of thyroid function testing exists. The aim of this study was to det...

ea0005p130 | Endocrine Tumours and Neoplasia | BES2003

Identification of the ACTH receptor in the human pituitary and its loss of expression in pituitary adenomas

Morris D , Kola B , Borboli N , Kaltsas G , Gueorguiev M , Jones T , Baldeweg S , Powell M , Korbonits M , Grossman A

The ACTH receptor (ACTH-R) is the second member of the melanocortin receptor family that includes five seven-transmembrane G protein-coupled receptors, and has been shown to be predominantly expressed in the adrenal cortex. It has been postulated that ACTH may regulate its own secretion through ultra-short loop feedback within the pituitary, and as ACTH-secreting adenomas are characterised by resistance to glucocorticoid feedback, they may also have dysregulated ACTH feedback....

ea0095p24 | Diabetes 1 | BSPED2023

A UK survey on the screening and management of childhood pre-clinical type 1 diabetes

Swaby Rabbi , Randell Tabitha , Scudder Claire , Bowen-Morris Jane , Townson Julia , Dayan Colin , Marcovecchio Loredana , Besser Rachel

Introduction: Type 1 diabetes (T1D) onset may start years prior to clinical presentation. Screening children and young people (CYP) for T1D using islet autoantibodies (IAb) through research studies is gaining international momentum, since screening reduces diabetic ketoacidosis, hospitalisation and offers access to drug therapies for delaying T1D onset1. Recently, ISPAD provided recommendations on monitoring for pre-clinical T1D in CYP, however no U...

ea0095p147 | Pituitary and Growth 2 | BSPED2023

Testing a screening algorithm for the identification of growth-disorders for use in UK children

Orr Joanna , Thaventhiran Thilipan , Freer Joseph , Walton Robert , Morris Joan K , Dunkel Leo , Prendergast Andrew J. , Storr Helen L.

Background: Screening algorithms for the identification of growth-disorders are routinely used in several countries. In the UK, the use of the Coventry consensus for the referral of children with suspected growth-disorders performs poorly compared to more sophisticated screening mechanisms used elsewhere. We aimed to test an algorithm developed to screen for growth-disorders in 2- to 8-year-old UK children.Methods: The a...

ea0077oc4.1 | Adrenal and Cardiovascular | SFEBES2021

Development of [18F]AldoView as the first highly selective aldosterone synthase PET tracer for imaging of patients with Primary Hyperaldosteronism.

Sander Kerstin , Gendron Thibault , Cybulska Klaudia A. , Sirindil Faith , Zhou Jonhua , Kalber Tammy L. , Lythgoe Mark F. , Kurzawinski Tom R. , Brown Morris J. , Arstad Erik

Background: Inappropriately high aldosterone in patients with primary hyperaldosteronism (PHA) is due to increased aldosterone synthase (CYP11B2) activity. Selective in vivo imaging of overexpressed CYP11B2 in adrenals with positron emission tomography (PET) has not yet been achieved due to close homology of enzymes involved in aldosterone and cortisol (CYP11B1) synthesis.Aim: Synthesize a fluorine-18 labelled highly selective CYP11B2 inhibitor,...

ea0077op2.1 | Adrenal and Cardiovascular | SFEBES2021

A phase 1 clinical trial evaluating the safety and efficacy of up to two administrations of the adrenal PET tracer [18F]CETO in healthy volunteers and patients with primary aldosteronism

Senanayake Russell , Gillett Daniel , Bashari Waiel , MacFarlane James , Hu Lihua , Palma August , Aloj Luigi , Mendichovszky Iosif , Hader Stefan , Boros Istvan , Brown Morris , Cheow Heok , Aigbirhio Franklin , Gurnell Mark

Background: Primary aldosteronism (PA) is an important, potentially curable, cause of hypertension. Distinguishing unilateral and bilateral causes is a critical step in determining who should be considered for adrenalectomy. Adrenal vein sampling (AVS) remains the gold standard for lateralisation. However, AVS is technically challenging with limited availability. To address this, we have introduced molecular imaging using PET/CT with the radiotracer [11C]Metomidate ...